Immune-Modulating Agents, Royal College of Physicians

Key message A subset of patients with COVID-19 may experience an exaggerated hyperinflammatory response COVID-19 associated hyperinflammation predominantly involves the lung however may progress to secondary haemophagocytic lymphohistocytosis (sHLH) which is a systemic and multi-organ condition with significant morbidity and mortality CTAG strongly recommends systemic corticosteroids for patients who fit definitions of WHO-defined severe or critical COVID-19, or in patients who otherwise have a new oxygen requirement CTAG also recommends not to use corticosteroid therapy i n patients with WHO-defined non-severe COVID-19 (i.e. the absence of any signs of severe or critical COVID-19) As far as possible, the use of investigative immunomodulatory medicines should be used in the context of a national priority clinical trial. This includes patients treated with remd esivir +/- corticosteroid Patients who meet diagnostic criteria for sHLH should be managed within established pathways, guided by a specialist familiar with hyperinflammation IVIG for PIMS-TS should ideally be used within the context of the RECOVERY clinical trial Advice on the a ppropriate use of remdesivir is available in the 2 External 0 0 0 CTAG Antivirals position statement false https://www.ctag-support.org.uk/antivirals true false%> Suspected side effects to medicines used in coronavirus treatment should be reported via the 2 External 0 0 0Yellow Card COVID-19 reporting si...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news